HIF-2 Alpha Inhibitor
Belzutifan for Kidney Cancer
Recruiting1 awardPhase 2
Washington, District of Columbia
This trial will compare the effectiveness of two doses of belzutifan in people with advanced kidney cancer that has spread after previous treatment. The higher dose is expected to be better in terms of tumor shrinkage.
Monoclonal Antibodies
Canakinumab + Spartalizumab for Renal Cell Carcinoma
Recruiting1 awardPhase < 1
New York, New York
This trial is testing a new cancer treatment involving two drugs, canakinumab and spartalizumab, to see if it is safe and effective. The trial will also assess the immune response to the treatment and the anti-tumor activity.
Chemotherapy
KFA115 + Tislelizumab for Advanced Cancers
Recruiting1 awardPhase 1
Toronto, Ontario
This trial tests a new drug, KFA115, alone and with pembrolizumab in patients with advanced cancers. It aims to find the safest dose and see if the drugs can reduce tumors. The focus is on patients whose cancers are hard to treat with current options.
Small Molecule
DFF332 + Combination Therapy for Renal Cell Carcinoma
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new drug called DFF332 in patients with advanced kidney cancer and other cancers with certain genetic mutations. The drug works by blocking a protein that helps the cancer grow.
Popular Filters
Trials for Kidney Cancer Patients
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
Monoclonal Antibodies
MEDI5752 + Axitinib/Lenvatinib for Kidney Cancer
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is testing a new drug called MEDI5752 combined with either Lenvatinib or Axitinib in patients with advanced kidney cancer. The new drug helps the immune system fight the cancer, while the other drugs stop the cancer cells from growing. The goal is to see if this combination is safe and effective. Axitinib is a drug approved for treating advanced kidney cancer.
CAR T-cell Therapy
A2B395 CAR T-Cell Therapy for Colorectal Cancer
Recruiting1 awardPhase 1 & 2
La Jolla, California
This trial aims to test a new treatment called A2B395 on patients with various types of solid tumors. The study will determine the safe dosage of A2B395 and evaluate its effectiveness in killing
Radioembolization
Radioembolization for Kidney Cancer
Recruiting1 awardPhase 1 & 2
London, Ontario
"This trial aims to test a new treatment for kidney cancer patients who cannot have surgery due to large tumors. The treatment involves using radioactive spheres containing Y-90 to deliver high doses of radiation to the tumors
Trials for Kidney Cell Carcinoma Patients
Cyclin-Dependent Kinase Inhibitor
NKT2152 + Palbociclib + Sasanlimab for Kidney Cancer
Recruiting1 awardPhase 2
Omaha, Nebraska
This trial is testing a new drug combination for patients with advanced kidney cancer who have already tried other treatments. The goal is to see if these drugs can work better together to stop cancer growth and help the immune system fight the disease.
Monoclonal Antibodies
MEDI5752 + Axitinib/Lenvatinib for Kidney Cancer
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is testing a new drug called MEDI5752 combined with either Lenvatinib or Axitinib in patients with advanced kidney cancer. The new drug helps the immune system fight the cancer, while the other drugs stop the cancer cells from growing. The goal is to see if this combination is safe and effective. Axitinib is a drug approved for treating advanced kidney cancer.
CAR T-cell Therapy
A2B395 CAR T-Cell Therapy for Colorectal Cancer
Recruiting1 awardPhase 1 & 2
La Jolla, California
This trial aims to test a new treatment called A2B395 on patients with various types of solid tumors. The study will determine the safe dosage of A2B395 and evaluate its effectiveness in killing
Radioembolization
Radioembolization for Kidney Cancer
Recruiting1 awardPhase 1 & 2
London, Ontario
"This trial aims to test a new treatment for kidney cancer patients who cannot have surgery due to large tumors. The treatment involves using radioactive spheres containing Y-90 to deliver high doses of radiation to the tumors
Phase 3 Trials
Kinase Inhibitor
Savolitinib vs. Sunitinib for Kidney Cancer
Recruiting2 awardsPhase 3
La Jolla, California
This trial is for patients with a certain type of kidney cancer that has spread and cannot be removed by surgery. The goal is to see if a new medication, savolitinib, is better than the current standard of care, sunitinib, and to learn about any side effects.
HIF-2 Alpha Inhibitor
Belzutifan + Pembrolizumab for Kidney Cancer
Recruiting1 awardPhase 3
Marietta, Georgia
This trial is testing a new treatment in patients who have had kidney cancer surgery. The goal is to see if this treatment can prevent the cancer from coming back. One part of the treatment stops cancer cells from surviving in low oxygen, and the other part helps the immune system attack the cancer. This approach has shown improved survival rates in treating advanced kidney cancer.
Trials With No Placebo
Chemotherapy
BMS-986340 + Nivolumab/Docetaxel for Cancer
Recruiting1 awardPhase 1 & 2
Hackensack, New Jersey
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
HIF-2alpha Inhibitor
Belzutifan for Kidney Cancer
Recruiting1 awardPhase 1
Ann Arbor, Michigan
This trial is testing belzutifan, a medication for patients with advanced kidney cancer that hasn't responded to previous treatments. The drug works by blocking a protein that cancer cells need to grow. Researchers aim to find out if it is safe and effective for these patients. Belzutifan has received FDA approval for treating von Hippel-Lindau-associated renal cell carcinoma and has shown significant efficacy in related tumors.
Monoclonal Antibodies
Immune + Targeted Therapies for Renal Cell Carcinoma
Recruiting1 awardPhase 1 & 2
Chicago, Illinois
This trial is a substudy of a larger study that is testing experimental treatments for renal cell carcinoma. The goal of this substudy is to see if the combination of investigational agents is safe and effective in people with advanced ccRCC.
Checkpoint Inhibitor
Immune and Targeted Combination Therapies for Kidney Cancer
Recruiting1 awardPhase 1 & 2
Chicago, Illinois
This trial is studying new combinations of drugs to treat renal cell carcinoma. The goal is to find new ways to treat this disease that are more effective and have fewer side effects than current treatments.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.